1. Home
  2. LTRN vs KZR Comparison

LTRN vs KZR Comparison

Compare LTRN & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$3.03

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Logo Kezar Life Sciences Inc.

KZR

Kezar Life Sciences Inc.

HOLD

Current Price

$6.15

Market Cap

44.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRN
KZR
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.7M
44.5M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
LTRN
KZR
Price
$3.03
$6.15
Analyst Decision
Strong Buy
Hold
Analyst Count
1
4
Target Price
$25.00
$6.00
AVG Volume (30 Days)
55.6K
36.8K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$3.53
52 Week High
$5.74
$6.65

Technical Indicators

Market Signals
Indicator
LTRN
KZR
Relative Strength Index (RSI) 38.24 46.28
Support Level $3.32 $6.03
Resistance Level $3.27 $6.23
Average True Range (ATR) 0.20 0.12
MACD -0.04 -0.01
Stochastic Oscillator 7.94 44.07

Price Performance

Historical Comparison
LTRN
KZR

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About KZR Kezar Life Sciences Inc.

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Share on Social Networks: